Polyplus-transfection® SA, today announces the investment in Shanghai commercial offices to expand localized cell and gene therapy sector supply.

StrasbourgFrance, July 28, 2021 – Polyplus-transfection® SAa leading provider of research through commercial grade upstream process solutions for advanced biologic and cell and gene therapy production, today announces it is investing in new commercial offices to increase the footprint and service offering in China.

“This premium office space in the heart of Shanghai’s Changning District enables Polyplus® to offer greater support to the booming Chinese cell and gene therapy industry,” commented Dr Jacob Qin, China Business Director at Polyplus®. “Our Shanghai team offers advanced scientific support and supply solutions for upstream processing technologies of pre-clinical, clinical and commercial cell and gene therapies manufacturing.”

Polyplus® products and services are deployed globally, including supply for many existing pre-clinical and clinical trials of AAV gene therapies. Continued growth in demand across the Chinese cell and gene therapy sector has driven the physical expansion into Asia-Pacific. In addition to this recent investment in Asia, the company continues to invest in other global regions, including construction of a new global headquarters of 4,000m2 at the Vectura facility in France.

The recent acquisition of Biowire, a Hong Kong based company supporting commercial development of life sciences tool and reagent companies in Asia, was the first step of the Polyplus® Asia Pacific growth plan. The global footprint of Polyplus will continue to grow via organic growth, strategic additions, and regional partnerships.

“Innovation in gene replacement therapy using Adeno Associated Virus (AAV) and gene modified cell therapies using lentiviral vectors (LV) is advancing rapidly across the globe. China has been a frontrunner in this race to new therapeutic modalities progress,” said Mario Philips, CEO of Polyplus®. “This growth has created tremendous demand for high performance, high quality transfection reagents, particularly for AAV gene therapy and CAR-T cell therapy treatments, in the region. We believe it is critical to invest in a physical presence in this market as we work to strategically expand our portfolio of products and services globally.”

The Shanghai location is currently active. Please feel free to contact the Polyplus® China office at



Learn more



Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility
Polyplus-transfection acquires Biowire to further expand into Asia-Pacific gene and cell therapy markets

View All Resources